{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T05:24:57Z","timestamp":1669613097791},"reference-count":7,"publisher":"American Scientific Publishers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["j nanosci nanotechnol"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>In recent years, mTOR signaling pathway has been found to be the main bridge between TSC1\/TSC2 gene mutation and tuberous sclerosis phenotype. Although mTOR inhibitors have been reported to treat tuberous sclerosis in foreign countries, there is still a lack of long-term follow-up results and clinical treatment experience in children. Therefore, research at home and abroad is actively focusing on the mTOR signaling pathway to further clarify the pathogenesis of the disease, and from a clinical point of view, to summarize the clinical data of more patients treated with mTOR inhibitors, to conduct a long-term follow-up and exploration of rapamycin treatment, and to summarize mature treatment experience. This is also the research hotspot of tuberous sclerosis. Based on the study of the treatment of tuberous sclerosis patients with rapamycin nanomicelles by abdominal ultrasound, the therapeutic effect and safety were compared and evaluated through the observation and description of the clinical seizure control and the recovery of EEG peak out of rhythm in children with tuberous sclerosis and infantile spasm.<\/jats:p>","DOI":"10.1166\/jnn.2021.18683","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:53:47Z","timestamp":1605243227000},"page":"962-970","source":"Crossref","is-referenced-by-count":1,"title":["Study on the Treatment of Tuberous Sclerosis with Rapamycin Nanomicelles Based on Abdominal Ultrasound"],"prefix":"10.1166","volume":"21","author":[{"given":"Xiaojun","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Ultrasound, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People\u2019s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Thyroid and Breast Surgical Department of Shenzhen People\u2019s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People\u2019s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Forensic Evidence, Shenzhen People\u2019s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People\u2019s Hospital, Second Clinical Medical College of Jinan University, Shenzhen 518020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17","reference":[{"issue":"(1)","key":"r1","doi-asserted-by":"crossref","first-page":"pp.279","DOI":"10.1016\/j.ijpharm.2016.05.064","article-title":"Formulation and characterization of a 0.1% rapamycin cream for the treatment of tuberous sclerosis complex-related angiofibromas.","volume":"509","author":"Bougu\u00e9on","year":"2016","journal-title":"International Journal of Pharmaceutics"},{"issue":"(11)","key":"r2","first-page":"pp.812","article-title":"Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis.","volume":"52","author":"Zou","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"(6)","key":"r3","first-page":"pp.728","article-title":"Recommendations for imaging-based diagnosis and management of renal angiomy-olipoma associated with tuberous sclerosis complex.","volume":"10","author":"Pradilla","year":"2017","journal-title":"CKJ: Clinical Kidney Journal"},{"issue":"(1)","key":"r4","doi-asserted-by":"crossref","first-page":"pp.63","DOI":"10.1111\/ajd.12125","article-title":"Topical rapamycin for angiofi-bromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions.","volume":"55","author":"Tu","year":"2014","journal-title":"Australasian Journal of Dermatology"},{"issue":"(3)","key":"r5","first-page":"pp.706","article-title":"A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copoly-mer.","volume":"31","author":"Tai","year":"2013","journal-title":"Pharmaceutical Research"},{"issue":"(15 Supplement)","key":"r6","doi-asserted-by":"crossref","first-page":"pp.3766","DOI":"10.1158\/1538-7445.AM2015-3766","article-title":"Identifying rational combination therapies with rapamycin for the treatment of epithelial cancers.","volume":"75","author":"Dawood","year":"2015","journal-title":"Cancer Research"},{"issue":"(39)","key":"r7","doi-asserted-by":"crossref","first-page":"pp.4702","DOI":"10.1038\/onc.2012.481","article-title":"mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.","volume":"32","author":"Peng","year":"2013","journal-title":"Oncogene"}],"container-title":["Journal of Nanoscience and Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/asp\/jnn\/2021\/00000021\/00000002\/art00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T23:01:03Z","timestamp":1669590063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.1166\/jnn.2021.18683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["1533-4880(20210201)21:2L.962;1-"],"URL":"https:\/\/doi.org\/10.1166\/jnn.2021.18683","relation":{},"ISSN":["1533-4880"],"issn-type":[{"value":"1533-4880","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}